A Study of Chinese Congenital Bicuspid Aortic Valve

Launched by RUIJIN HOSPITAL · Jan 25, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on studying a heart condition called bicuspid aortic valve (BAV), which is believed to be more common in people from China. The researchers are looking to gather information on how BAV progresses and how effective different treatments are. They want to create a group of patients with BAV to closely monitor their health and treatment responses over time.

If you or someone you know is between the ages of 14 and 60 and has been diagnosed with BAV through specific heart imaging tests, you may be eligible to participate. To join, individuals must agree to the study’s terms and sign a consent form. Participants can expect regular follow-ups and will help researchers better understand this condition, which could lead to improved treatments in the future. However, certain health issues, like severe anemia or other heart valve diseases, may prevent someone from joining the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The patients were aged 14-60 years;
• • Definitive diagnosis of BAV by imaging (echocardiography, aortic CTA, cardiac magnetic resonance, etc.)
• • Patients were informed about the nature of the study and agreed to participate in all the terms of the study and signed an informed consent form approved by the ethics committee.
• Exclusion Criteria:
• • Poor patient compliance and inability to complete follow-up visits as required;
• • Rheumatic heart valve disease, other organic valve disease.
• • Hyperthyroidism, severe anemia, and other factors that significantly affect hemodynamics.
• • Other circumstances that the researcher believes should be excluded.